(Q41121843)

27 September 2017

title

Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy (English)

1 reference

27 September 2017

1

Chloe L Thio

1 reference

27 September 2017

4

Kenrad E Nelson

1 reference

27 September 2017

5

Stephan Ehrhardt

1 reference

27 September 2017

Nan Guo

2

1 reference

27 September 2017

Chan Xie

series ordinal

3

1 reference

27 September 2017

publication date

2 July 2015

1 reference

Lancet Infectious Diseases

27 September 2017

published in

1 reference

27 September 2017

volume

15

1 reference

27 September 2017

issue

8

1 reference

27 September 2017

page(s)

981-985

1 reference

Hepatitis B: Epidemiology and prevention in developing countries.

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

The next step in controlling HBV in China.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Findings from a hepatitis B birth dose assessment in health facilities in the Philippines: opportunities to engage the private sector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

HBV treatment and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Screening of pregnant women for hepatitis B virus surface antigen (HBsAg) and subsequent management, Qiandongnan prefecture, Guizhou, China, 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Management of hepatitis B during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Prevention of neonatal hepatitis B virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980-2010).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Eliminating mother to child transmission of HIV-1 and keeping mothers alive: recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

HIV-HBV coinfection--a global challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

Eliminating mother-to-child HIV transmission in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900158-9

7 January 2021

10.1016/S1473-3099(15)00158-9

Identifiers

DOI

1 reference

27 September 2017

1 reference